HEPION PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $35.6M | $33.3M | $20.4M | $12.0M |
| SG&A Expense | $9.6M | $10.3M | $10.0M | $8.1M |
| Operating Income | $-48.4M | $-45.5M | $-30.4M | $-20.1M |
| Operating Margin | — | — | — | — |
| Interest Expense | $9.5K | $10.2K | $8.9K | $31.2K |
| Pretax Income | $-49.3M | $-45.1M | $-32.7M | $-20.3M |
| Income Tax Expense | $-409.0K | $-2.9M | $0 | $30.6K |
| Net Income | $-48.9M | $-42.2M | $-32.7M | $-20.4M |
| Net Margin | — | — | — | — |
| EPS (Basic) | $-8.00 | $-0.15 | $-0.01 | $0.00 |
| EPS (Diluted) | $-8.00 | $-0.15 | $-0.01 | $0.00 |
| Shares Outstanding (Basic) | 6.1M | 293.5M | 5.41B | 5.22B |
| Shares Outstanding (Diluted) | 6.1M | 293.5M | 5.41B | 5.22B |
| Dividends Per Share | — | — | — | — |